Isatuximab is another anti-CD38 IgG kappa monoclonal antibody with a similar mechanism of action as daratumumab and is characterized by a strong anti-myeloma activity via direct tumor cell killing and a unique direct proapoptotic effect independent of Fc crosslinking [44]. This evidence concerns the gene CD38 and plasma cell myeloma.